Portal de Periódicos da CAPES

Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas

2007; Ferrata Storti Foundation; Volume: 92; Issue: 5 Linguagem: Inglês

10.3324/haematol.10879

1592-8721

Stefano Pulini, Serena Rupoli, Gaia Goteri, Nicola Pimpinelli, Renato Alterini, Angela Tassetti, Anna Rita Scortechini, Massimo Offidani, Simonetta Mulattieri, Andrea Stronati, Giuliano Brandozzi, Alfredo Giacchetti, Giorgio Mozzicafreddo, G. Ricotti, Giorgio Filosa, Alberta Bettacchi, M. Simonacci, N. L. Rodrigues E. L. B. Novelli, Pietro Leoni,

Fungal Infections and Studies

Pegylated liposomal doxorubicin (Peg-Doxo) is a promising drug for advanced/recalcitrant primary cutaneous T-cell lymphomas (CTCLs). This prospective phase II trial enrolled 19 patients. We observed overall and complete response rates of 84.2% and 42.1% (with no significant differences between stage I–IIA and IIB–IV patients), and 11% grade III/IV toxicity. After a maximum 46 month-follow-up, median overall (OS), event-free (EFS) and progression-free (PFS) survival were 34, 18 and 19 months. OS, EFS and PFS rates at 46 months were 44%, 30% and 37% respectively. Peg-Doxo seems to be an active and safe principle that should be used in plurirelapsed, early stage-MF and in combination with other chemotherapeutic agents in advanced and aggressive CTCLs.